Why the study?
Pseudomyogenic hemangioendothelioma is rarely encountered, and fewer than 20 cases with exclusive involvement of bone structures have been reported.
18F-FDG PET/CT can be used to image rare cases of pseudomyogenic hemangioendothelioma with exclusive bone involvement during mTOR inhibitor treatment.
Hemangioendotheliomas are a heterogeneous group of vascular neoplasm that may affect the liver, bone, and soft tissues. Among its variants, pseudomyogenic hemangioendothelioma is rarely encountered. Pseudomyogenic hemangioendothelioma is usually characterized by multiple soft tissue lesions, with occasional bone lesions. Fewer than 20 cases with exclusive involvement of bone structures have been reported. We describe a case of pseudomyogenic hemangioendothelioma involving multiple bony structures but without soft tissue involvement in a 7-year-old girl, imaged with F-FDG PET/CT at diagnosis and during treatment with mammalian target of rapamycin inhibitors.
No takes yet. Share an insight, caveat, or question.
Plouznikoff et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: